FDA approve Alimta & Keytruda for combination lung cancer treatment

The US regulators have approved a combination of Eli Lilly’s Alimta and MSD’s Keytruda as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status. The combination was approved via the FDA’s accelerated approval pathway based on Phase II tumour response rate and progression-free survival (PFS) data observed

Continue Reading

World’s Largest Cell and Gene Therapy Plant Opens

Recently, Swiss biotech company Lonza officially opened its new cell and gene therapy manufacturing plant in Pearland, near Houston, Texas. The facility’s 300,000 square feet make it the world’s largest manufacturing plant devoted to making these types of materials, according to a statement. “This facility has the potential to produce treatment for thousands of patients

Continue Reading

Hamilton Researchers find blood thinner reduces risk of death after non-cardiac surgery

Researchers have discovered that a blood-thinning drug, dabigatran, can significantly reduce the risk of death, heart attack, stroke, and other heart or blood-vessel complications in patients who have a heart injury following major, non-cardiac surgery. Every year, around eight million people in the world develop a condition called myocardial injury after non-cardiac surgery (MINS), which

Continue Reading

FDA approves investigational new drug application for treatment of mucopolysaccharidosis type IIIA

Swedish Biopharmaceutical company, Swedish Orphan Biovitrum AB has announced that the FDA has issued a “study may proceed” letter for the first study in humans, thereby accepting the investigational new drug (IND) application for the drug candidate SOBI003 for the treatment of mucopolysaccharidosis type IIIA. In addition, SOBI003 was granted Fast Track status by the

Continue Reading